DHF
MCID: DNG002
MIFTS: 59

Dengue Hemorrhagic Fever (DHF)

Categories: Blood diseases, Infectious diseases

Aliases & Classifications for Dengue Hemorrhagic Fever

MalaCards integrated aliases for Dengue Hemorrhagic Fever:

Name: Dengue Hemorrhagic Fever 12 54 15 17
Dengue Haemorrhagic Fever 12 32
Severe Dengue 44 70
Dhf 12

Classifications:



External Ids:

Disease Ontology 12 DOID:12206
MeSH 44 D019595
NCIt 50 C34683
SNOMED-CT 67 20927009
ICD10 32 A91
UMLS 70 C0019100

Summaries for Dengue Hemorrhagic Fever

Disease Ontology : 12 A dengue disease that occurs when a person experiences a second infection with a heterologous Dengue virus serotype, which is transmitted by Aedes mosquito bite. The infection has symptom hemorrhagic lesions of the skin, has symptom thrombocytopenia, has symptom reduction in the fluid part of the blood, and has symptom high fever.

MalaCards based summary : Dengue Hemorrhagic Fever, also known as dengue haemorrhagic fever, is related to dengue disease and dengue virus, and has symptoms including thrombocytopenia, high fever and hemorrhagic lesions of the skin. An important gene associated with Dengue Hemorrhagic Fever is CD209 (CD209 Molecule), and among its related pathways/superpathways are Innate Immune System and Viral mRNA Translation. The drugs Histamine and Ketotifen have been mentioned in the context of this disorder. Affiliated tissues include endothelial, monocytes and t cells, and related phenotypes are homeostasis/metabolism and hematopoietic system

Related Diseases for Dengue Hemorrhagic Fever

Diseases related to Dengue Hemorrhagic Fever via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 868)
# Related Disease Score Top Affiliating Genes
1 dengue disease 32.9 TNF IL10 IFNG IFNB1 IFNA1 CD209
2 dengue virus 32.7 TNF STAT2 CD209
3 dengue shock syndrome 31.3 TNF STAT2 IL6 IFNA1 HLA-A CD209
4 cholecystitis 31.3 GPT F2 ALB
5 acute kidney failure 31.1 GPT F2 ALB
6 acalculous cholecystitis 31.0 GPT F2 ALB
7 pulmonary edema 30.8 TNF IL10 F2 CXCL8
8 anuria 30.8 F3 F2 ALB
9 eclampsia 30.7 TNF F2 ALB
10 hepatic coma 30.7 GPT F3 F2 ALB
11 disseminated intravascular coagulation 30.7 TNF IL6 IL10 GPT F3 F2
12 femoral neuropathy 30.6 F3 F2
13 epidemic typhus 30.6 TNF IL10 GPT
14 reye syndrome 30.6 GPT F2 ALB
15 hemophagocytic lymphohistiocytosis 30.6 TNF IL10 IFNG GPT CXCL8
16 active peptic ulcer disease 30.6 F3 F2 ALB
17 cardiac tamponade 30.6 F3 F2 ALB
18 hantavirus pulmonary syndrome 30.5 IFNB1 F3 F2
19 acute myocarditis 30.5 TNF TLR3 STAT1 IL10
20 analbuminemia 30.5 GPT F3 F2 ALB
21 encephalitis 30.5 TNF TLR3 IL6 IL10 IFNB1 CD209
22 myocarditis 30.4 TNF TLR3 IL6 IL4 IL10 IFNG
23 japanese encephalitis 30.4 TNF TLR7 TLR3 STAT2 STAT1 IFNB1
24 hepatitis 30.4 TNF IFNG IFNA1 GPT F2
25 chikungunya 30.4 TNF TLR7 STAT1 IL6 CD209
26 metabolic acidosis 30.4 IL6 GPT F2 ALB
27 cardiogenic shock 30.4 TNF IL6
28 lymphopenia 30.4 IL6 IL4 IL10 IFNG
29 acute pancreatitis 30.3 TNF IL6 IL10 GPT CXCL8
30 filariasis 30.3 TNF IL6 IL10 IFNG ALB
31 hepatic encephalopathy 30.3 TNF IL6 GPT F2 ALB
32 optic nerve disease 30.3 TNF IL6 IFNB1 ALB
33 compartment syndrome 30.3 TNF IL6 GPT F3 F2 ALB
34 peptic ulcer disease 30.3 TNF IL10 CXCL8
35 adult respiratory distress syndrome 30.3 TNF IL6 IL10 F2 CXCL8
36 yellow fever 30.2 STAT1 IL6 IL4 IFNB1 IFNAR1
37 crohn's colitis 30.2 TNF IFNG CXCL8
38 typhoid fever 30.2 TNF IL6 IFNG GPT F2 ALB
39 haemophilus influenzae 30.2 TNF CXCL8
40 end stage renal disease 30.1 TNF IL6 IL10 ALB
41 endophthalmitis 30.1 TNF IL6 CXCL8 ALB
42 schistosomiasis 30.1 TNF IL4 IL10 IFNG GPT F2
43 pericardial effusion 30.0 IL6 GPT F3 F2 ALB
44 zika fever 30.0 TLR3 STAT2 IFNAR1 CD209
45 neutropenia 30.0 TNF IL6 IL10 IFNA1 GPT CXCL8
46 hemolytic anemia 30.0 TNF IL4 IL10 IFNG IFNA1 F3
47 purpura 30.0 TNF IL6 IL4 IL10 IFNG F3
48 gastritis 30.0 TNF IL6 IL10 CXCL8
49 exanthem 30.0 TNF IL6 IL10 IFNG IFNA1 GPT
50 acquired immunodeficiency syndrome 29.9 TNF IL6 IL10 IFNG IFNA1 ALB

Graphical network of the top 20 diseases related to Dengue Hemorrhagic Fever:



Diseases related to Dengue Hemorrhagic Fever

Symptoms & Phenotypes for Dengue Hemorrhagic Fever

Symptoms:

12
  • thrombocytopenia
  • high fever
  • hemorrhagic lesions of the skin
  • reduction in the fluid part of the blood

MGI Mouse Phenotypes related to Dengue Hemorrhagic Fever:

46 (show all 14)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.4 ALB CD209 F2 F3 FCGR2A IFNAR1
2 hematopoietic system MP:0005397 10.39 CD209 F3 FCGR2A HLA-A IFNAR1 IFNB1
3 immune system MP:0005387 10.38 ALB F2 F3 FCGR2A HLA-A IFNAR1
4 mortality/aging MP:0010768 10.28 ALB F2 F3 FCGR2A HLA-A IFNAR1
5 endocrine/exocrine gland MP:0005379 10.26 ALB F2 HLA-A IFNAR1 IFNG IL10
6 digestive/alimentary MP:0005381 10.19 ALB F2 IFNAR1 IFNG IL10 IL4
7 integument MP:0010771 10.11 F2 F3 IFNAR1 IFNG IL10 IL4
8 liver/biliary system MP:0005370 10.03 ALB IFNAR1 IFNG IL10 IL4 IL6
9 nervous system MP:0003631 10.03 F2 F3 HLA-A IFNAR1 IFNB1 IFNG
10 muscle MP:0005369 10.02 ALB F2 F3 IFNG IL10 IL6
11 neoplasm MP:0002006 10.02 ALB F3 IFNAR1 IFNB1 IFNG IL10
12 no phenotypic analysis MP:0003012 9.7 HLA-A IFNAR1 IFNB1 IFNG IL10 IL4
13 respiratory system MP:0005388 9.65 F2 F3 IFNAR1 IFNG IL10 IL4
14 skeleton MP:0005390 9.36 F2 FCGR2A GPT IFNAR1 IFNB1 IFNG

Drugs & Therapeutics for Dengue Hemorrhagic Fever

Drugs for Dengue Hemorrhagic Fever (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 24)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Histamine Approved, Investigational Phase 4 51-45-6, 75614-87-8 774
2
Ketotifen Approved Phase 4 34580-14-8, 34580-13-7 3827
3 Neurotransmitter Agents Phase 4
4 Histamine Antagonists Phase 4
5
Histamine Phosphate Phase 4 51-74-1 65513
6 Dermatologic Agents Phase 4
7 Histamine H1 Antagonists Phase 4
8 Anti-Allergic Agents Phase 4
9
tannic acid Approved Phase 3 1401-55-4
10
Benzocaine Approved, Investigational Phase 3 1994-09-7, 94-09-7 2337
11
Montelukast Approved Phase 2, Phase 3 158966-92-8 5281040
12 Heptavalent Pneumococcal Conjugate Vaccine Phase 3
13 Pharmaceutical Solutions Phase 3
14 Respiratory System Agents Phase 2, Phase 3
15 Anti-Asthmatic Agents Phase 2, Phase 3
16 Hormone Antagonists Phase 2, Phase 3
17 Hormones Phase 2, Phase 3
18 Leukotriene Antagonists Phase 2, Phase 3
19 Vaccines Phase 3
20 Immunologic Factors Phase 3
21
Ivermectin Approved, Investigational, Vet_approved Phase 2 70288-86-7 6474909
22 Hemostatics Phase 2
23 Antiparasitic Agents Phase 2
24 Anti-Infective Agents Phase 2

Interventional clinical trials:

(show all 44)
# Name Status NCT ID Phase Drugs
1 Ketotifen as a Treatment for Vascular Leakage During Dengue Fever (KETODEN) Unknown status NCT02673840 Phase 4 Ketotifen;Placebo
2 The Effect of Hypertonic Sodium Lactate on sVCAM-1 Level as a Surrogate Marker of Endothelial Capillary Leakage in Pediatric Dengue Shock Syndrome Patients Unknown status NCT00966628 Phase 3 Hypertonic sodium lactate;Ringer's lactate
3 Lot-to-Lot Consistency and Bridging Study of a Tetravalent Dengue Vaccine in Healthy Adults in Australia Completed NCT01134263 Phase 3
4 Immunogenicity and Safety of Yellow Fever Vaccine (Stamaril®) Administered Concomitantly With Tetravalent Dengue Vaccine in Healthy Toddlers at 12-13 Months of Age in Colombia and Peru Completed NCT01436396 Phase 3
5 Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Cervarix® in Healthy Female Subjects Aged 9 to 14 Years in Mexico Completed NCT02979535 Phase 3
6 Safety and Immunogenicity of a Tetravalent Dengue Vaccine in Healthy Children Aged 2 to 11 Years in Malaysia Completed NCT01254422 Phase 3
7 Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Gardasil® in Healthy Subjects Aged 9 to 13 Years in Malaysia Completed NCT02993757 Phase 3
8 Efficacy and Safety of a Novel Tetravalent Dengue Vaccine in Healthy Children Aged 2 to 14 Years in Asia Completed NCT01373281 Phase 3
9 Efficacy and Safety of a Novel Tetravalent Dengue Vaccine in Healthy Children and Adolescents Aged 9 to 16 Years in Latin America Completed NCT01374516 Phase 3
10 Immunogenicity and Safety of a Booster Injection of DTaP-IPV//Hib (Pentaxim™) Administered Concomitantly With Tetravalent Dengue Vaccine in Healthy Toddlers Aged 15 to 18 Months in Mexico Completed NCT01411241 Phase 3
11 Effect of Montelukast in Preventing Dengue With Warning Signs in Dengue Patients: a Multicenter Randomized, Double-blind, Placebo Controlled, Superiority Trial Recruiting NCT04673422 Phase 2, Phase 3 Montelukast;Placebo
12 Albumin 5% as Resuscitation in Adult Dengue Fever Patients With Plasma Leakage Recruiting NCT04076254 Phase 3 Albumins;Fluid
13 Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Adacel® in Healthy Subjects Aged 9 to 60 Years in the Philippines Terminated NCT02992418 Phase 3
14 A Multi-centre, Randomised, Double-blind, Parallel Group, Placebo-controlled Comparison of Recombinant Factor VIIa (NovoSeven®) and Standard Haemostatic Replacement Therapy in Patients With Dengue Haemorrhagic Fever Completed NCT01601613 Phase 2 activated recombinant human factor VII;placebo
15 Pharmacokinetics and Pharmacodynamics of Ivermectin in Pediatric Dengue Patients Completed NCT03432442 Phase 2 Ivermectin
16 Immunogenicity and Safety of CYD Dengue Vaccine in Healthy Toddlers Aged 12 to 15 Months in the Philippines Completed NCT01064141 Phase 2
17 Phase II, Randomized, Double-blind, Placebo-controlled Study of Two Doses of WRAIR Live Attenuated Tetravalent Dengue Vaccine Formulations, Administered Six Months Apart, to Healthy Adults and Children Completed NCT00468858 Phase 2
18 Evaluation of the Immune Response to Different Schedules of a Tetravalent Dengue Vaccine Administered With or Without Yellow Fever Vaccine in US Adults. Completed NCT01488890 Phase 2
19 Immunogenicity and Safety of CYD Dengue Vaccine in Healthy Children and Adolescents Aged 9 to 16 Years in South America Completed NCT01187433 Phase 2
20 Immunogenicity and Safety of a Tetravalent Dengue Vaccine Given as a Booster Injection in Adolescents and Adults Who Previously Completed the 3-dose Schedule in a Study Conducted in Singapore Completed NCT02824198 Phase 2
21 Immunogenicity and Safety of Three Tetravalent Formulations of Dengue Vaccine Candidates in Healthy Adults Aged 18 to 45 Years in the US Completed NCT00617344 Phase 2
22 Immunogenicity and Safety of Tetravalent Dengue Vaccine Given in 1-, 2-, or 3- Dose Schedules (STAGE I) Followed by a Single Booster Injection of the Same Vaccine (STAGE II) 1 or 2 Years After the Last Primary Dose in Healthy Subjects 9 to 50 Years of Age in Colombia and the Philippines Completed NCT02628444 Phase 2
23 Safety and Immunogenicity of Bivalent and Tetravalent Formulations of Dengue Vaccine Candidates in Healthy Flavivirus-Naïve Adults Aged 18 to 45 Years Completed NCT00740155 Phase 2
24 Immunogenicity and Safety of a Tetravalent Dengue Vaccine Given as a Booster Injection in Adolescents and Adults Who Previously Completed the 3-dose Schedule in a Study Conducted in Latin America Completed NCT02623725 Phase 2
25 Immunogenicity and Safety of Sanofi Pasteur's CYD Dengue Vaccine in Healthy Children and Adolescents Aged 9 to 16 Years in Latin America Completed NCT00993447 Phase 2
26 Immunogenicity and Safety of ChimeriVax™ Tetravalent Dengue Vaccine in Healthy Children Aged 2 to 11 Years Previously Vaccinated Against Yellow Fever in Peru Completed NCT00788151 Phase 2
27 Exploration of Immunologic Mechanisms of Immune Interference and/or Cross-Neutralizing Immunity Following Various Administration Schedules With CYD Tetravalent Dengue Vaccine Completed NCT01943825 Phase 2
28 Immunogenicity and Safety of a Tetravalent Dengue Vaccine in Healthy Adult Subjects Aged 18 to 45 Years in India. Completed NCT01550289 Phase 2
29 Immunogenicity and Large-Scale Safety of Tetravalent Dengue Vaccine in Healthy Subjects Aged 2 to 45 Years in Singapore Completed NCT00880893 Phase 2
30 Immunogenicity and Safety of ChimeriVax™ Tetravalent Dengue Vaccine in Healthy Subjects Aged 2 to 45 Years in Viet Nam Completed NCT00875524 Phase 2
31 Efficacy and Safety of Dengue Vaccine in Healthy Children Aged 4 to 11 Years in Thailand Completed NCT00842530 Phase 2
32 Safety of ChimeriVax™ Dengue Tetravalent Vaccine in Adult Subjects Previously Immunised With an Investigational Dengue or Yellow Fever Vaccine Completed NCT00730288 Phase 2
33 Safety and Immunogenicity of a Tetravalent Dengue Vaccine in HIV-Positive Adults Aged 18 to 50 Years in Brazil Active, not recruiting NCT02741128 Phase 2
34 Evaluation of the Safety and Immunogenicity of Heterologous Dengue Vaccine Administration in Dengue Immune Individuals Completed NCT00458120 Phase 1
35 Phase I Evaluation of the Safety and Immunogenicity of rDEN4delta30 Lot# 109A, a Live Attenuated DEN4 Vaccine, in Healthy Flavivirus-naïve Adult Volunteers. Completed NCT00919178 Phase 1
36 Prospective Study for the Evaluation of Dengue Prognostic Biomarkers in Singapore Completed NCT04048837
37 Association of Host Genetics With Vaccine Efficacy, and Evaluation of Immune Correlates of Risk From the First Proof of Concept Efficacy Study With a Tetravalent Dengue Vaccine Completed NCT02827162
38 Prospective Dengue Seroprevalence Study in 5 to 10 Year-old Children in India Completed NCT01477671
39 Laboratory Diagnosis and Prognosis of Severe Dengue Completed NCT01421732
40 Long-Term Follow-Up of Hospitalized Dengue and Safety in Thai Children Who Were Included in an Efficacy Study of a Tetravalent Dengue Vaccine Completed NCT01983553
41 Descriptive and Prognostic Study of Arbovirus Infections in France, Based on a Hospital Cohort of Children and Adults With Suspected Arbovirose. Recruiting NCT01099852
42 Effectiveness of the Tetravalent Dengue Vaccine, CYD-TDV (Dengvaxia®) in the Philippines Recruiting NCT03803618
43 Effect of Baseline Dengue Serostatus Among Tetravalent Dengue Vaccine CYDTDV (Dengvaxia®) Recipients on Subsequent Virologically Confirmed Dengue in the Philippines Active, not recruiting NCT03465254
44 Post-Authorization Safety Study: Cohort Event Monitoring for Dengvaxia®, CYD-TDV Dengue Vaccine Active, not recruiting NCT02948933

Search NIH Clinical Center for Dengue Hemorrhagic Fever

Cochrane evidence based reviews: severe dengue

Genetic Tests for Dengue Hemorrhagic Fever

Anatomical Context for Dengue Hemorrhagic Fever

MalaCards organs/tissues related to Dengue Hemorrhagic Fever:

40
Endothelial, Monocytes, T Cells, Kidney, Liver, Myeloid, Pituitary

Publications for Dengue Hemorrhagic Fever

Articles related to Dengue Hemorrhagic Fever:

(show top 50) (show all 2881)
# Title Authors PMID Year
1
Super induction of dengue virus NS1 protein in E. coli. 61 54
19232392 2009
2
TNF and LTA gene, allele, and extended HLA haplotype associations with severe dengue virus infection in ethnic Thais. 61 54
19392621 2009
3
Recombinant non-structural 1 (NS1) protein of dengue-2 virus interacts with human STAT3beta protein. 61 54
15878791 2005
4
High circulating levels of the dengue virus nonstructural protein NS1 early in dengue illness correlate with the development of dengue hemorrhagic fever. 54 61
12355369 2002
5
Kinetics of dengue virus-specific serum immunoglobulin classes and subclasses correlate with clinical outcome of infection. 61 54
11724841 2001
6
Retrospective meta-transcriptomic identification of severe dengue in a traveller returning from Africa to Sweden, 1990. 61
33553563 2021
7
Accuracy and efficacy of pre-dengue vaccination screening for previous dengue infection with five commercially available immunoassays: a retrospective analysis of phase 3 efficacy trials. 61
33212068 2021
8
Dengue fever after coronary artery bypass grafting with ventricular dysfunction. 61
33016077 2021
9
Cytokine Signature of Dengue Patients at Different Severity of the Disease. 61
33809042 2021
10
A hospital based cross-sectional study on platelet parameters in adult patients with dengue, its serological subgroups, and controls. 61
33784226 2021
11
A Bibliometric Analysis on Dengue Outbreaks in Tropical and Sub-Tropical Climates Worldwide Since 1950. 61
33808795 2021
12
Differential expression analysis and profiling of hepatic miRNA and isomiRNA in dengue hemorrhagic fever. 61
33692368 2021
13
Cytokine IP-10 and GM-CSF are prognostic biomarkers for severity in secondary dengue infection. 61
33766427 2021
14
Severe dengue outbreak associated with DENV-3 in the city of Manado, North Sulawesi, Indonesia. 61
33774189 2021
15
Peritoneal dialysis in critically ill children in resource-limited setting: A prospective cohort study. 61
33272115 2021
16
Dynamic Airway Driving Pressure and Outcomes in Children With Acute Hypoxemic Respiratory Failure. 61
33024000 2021
17
Dengue and metabolomics in humans. 61
33712974 2021
18
Severe ocular and adnexal complications in dengue hemorrhagic fever: A report of 29 eyes. 61
33595487 2021
19
Alpha-mangostin inhibits dengue virus production and pro-inflammatory cytokine/chemokine expression in dendritic cells. 61
33782775 2021
20
Changes in complement alternative pathway components, factor B and factor H during dengue virus infection in the AG129 mouse. 61
33410734 2021
21
A Dengue Virus Serotype 1 mRNA-LNP Vaccine Elicits Protective Immune Responses. 61
33762420 2021
22
Expression dynamics of vascular endothelial markers: endoglin and syndecan-1 in predicting dengue disease outcome. 61
33567345 2021
23
Safety of temporary interruption of antiplatelet therapy in dengue fever with thrombocytopenia. 61
33271172 2021
24
Case Report: Severe COVID-19 and Dengue in an Indonesian Infant. 61
33626019 2021
25
Instability of the NS1 Glycoprotein from La Reunion 2018 Dengue 2 Virus (Cosmopolitan-1 Genotype) in Huh7 Cells Is Due to Lysine Residues on Positions 272 and 324. 61
33669407 2021
26
Fatal outcomes of imported dengue fever in adult travelers from non-endemic areas are associated with primary infections. 61
33590860 2021
27
Full-Length Genome and Partial Viral Genes Phylogenetic and Geographical Analysis of Dengue Serotype 3 Isolates. 61
33557307 2021
28
Risk predictors of progression to severe disease during the febrile phase of dengue: a systematic review and meta-analysis. 61
33640077 2021
29
Dengue Virus Serotype 2 Intrahost Diversity in Patients with Different Clinical Outcomes. 61
33672226 2021
30
Is there any association between body mass index and severity of dengue infection? 61
33587144 2021
31
Emergence of genotype I of dengue virus serotype 3 during severe dengue epidemic in Sri Lanka, 2017. 61
33642435 2021
32
High performance dengue virus antigen-based serotyping-NS1-ELISA (plus): A simple alternative approach to identify dengue virus serotypes in acute dengue specimens. 61
33635874 2021
33
Complicated Dengue Fever and Its Treatment Dilemmas: A Single-Center Experience in Sri Lanka. 61
33520320 2021
34
Association of dengue disease severity and blood group: A systematic review and meta-analysis. 61
32776660 2021
35
Urinary leukotrienes and histamine in patients with varying severity of acute dengue. 61
33544746 2021
36
Leucocytosis and early organ involvement as risk factors of mortality in adults with dengue fever. 61
33390410 2021
37
Dengue Infections and the Surgical Patient. 61
33200725 2021
38
Expression of Nitric Oxide Synthase and Nitric Oxide Levels in Peripheral Blood Cells and Oxidized Low-Density Lipoprotein Levels in Saliva as Early Markers of Severe Dengue. 61
33628800 2021
39
Ultrasound in Dengue: A Scoping Review. 61
33534759 2021
40
Early hematological parameters as predictors for outcomes in children with dengue in northern India: A retrospective analysis. 61
33533817 2021
41
Increased levels of pentraxins protein and cytokines bear good association in patients with severe dengue infection. 61
33436908 2021
42
Independent Evaluation of Two Prototype Immunochromatographic Tests for Dengue Fever Developed by InBios. 61
33428750 2021
43
Ivermectin Accelerates Circulating Nonstructural Protein 1 (NS1) Clearance in Adult Dengue Patients: A Combined Phase 2/3 Randomized Double-blinded Placebo Controlled Trial. 61
33462580 2021
44
Another dengue fever outbreak in Eastern Ethiopia-An emerging public health threat. 61
33465086 2021
45
Exposure to Dengue Envelope Protein Domain III Induces Nlrp3 Inflammasome-Dependent Endothelial Dysfunction and Hemorrhage in Mice. 61
33717109 2021
46
Dengue-chikungunya coinfection outbreak in children from Cali, Colombia in 2018-2019. 61
33075526 2021
47
Fatal subarachnoid haemorrhage in a patient with severe dengue. 61
33510120 2021
48
Whole Genome Sequencing of Dengue Virus Serotype 2 from Two Clinical Isolates and Serological Profile of Dengue in the 2015-2016 Nepal Outbreak. 61
33073748 2021
49
Current Understanding of the Pathogenesis of Dengue Virus Infection. 61
33231723 2021
50
Genetic diversity of the dengue virus population in dengue fever and dengue hemorrhagic fever patients. 61
33386790 2021

Variations for Dengue Hemorrhagic Fever

Expression for Dengue Hemorrhagic Fever

LifeMap Discovery
Genes differentially expressed in tissues of Dengue Hemorrhagic Fever patients vs. healthy controls: 35 (show top 50) (show all 120)
# Gene Description Tissue Up/Dn Fold Change (log2) P value
1 CD38 CD38 molecule Blood + 4.80 0.000
2 IFI27 interferon alpha inducible protein 27 Blood + 4.71 0.000
3 RRM2 ribonucleotide reductase regulatory subunit M2 Blood + 4.63 0.000
4 IGHM immunoglobulin heavy constant mu Blood + 4.61 0.000
5 BIRC5 baculoviral IAP repeat containing 5 Blood + 4.47 0.000
6 CAV1 caveolin 1 Blood + 4.41 0.000
7 DLGAP5 DLG associated protein 5 Blood + 4.31 0.000
8 XIST X inactive specific transcript Blood - 4.31 0.023
9 CEP55 centrosomal protein 55 Blood + 4.28 0.000
10 BUB1 BUB1 mitotic checkpoint serine/threonine kinase Blood + 4.21 0.000
11 SHCBP1 SHC binding and spindle associated 1 Blood + 4.13 0.000
12 PBK PDZ binding kinase Blood + 4.13 0.000
13 IGKV3-20 immunoglobulin kappa variable 3-20 Blood + 4.13 0.000
14 TYMS thymidylate synthetase Blood + 4.07 0.000
15 CDCA2 cell division cycle associated 2 Blood + 4.06 0.000
16 MKI67 marker of proliferation Ki-67 Blood + 4.00 0.000
17 CYAT1 immunoglobulin lambda light chain-like Blood + 3.98 0.000
18 MCM10 minichromosome maintenance 10 replication initiation factor Blood + 3.98 0.000
19 CCN3 cellular communication network factor 3 Blood - 3.97 0.000
20 ZWINT ZW10 interacting kinetochore protein Blood + 3.96 0.000
21 CDK1 cyclin dependent kinase 1 Blood + 3.92 0.000
22 HMMR hyaluronan mediated motility receptor Blood + 3.90 0.000
23 SDC1 syndecan 1 Blood + 3.89 0.000
24 SPC25 SPC25 component of NDC80 kinetochore complex Blood + 3.84 0.000
25 NCAPG non-SMC condensin I complex subunit G Blood + 3.84 0.000
26 TK1 thymidine kinase 1 Blood + 3.82 0.000
27 CDC20 cell division cycle 20 Blood + 3.80 0.000
28 TNFRSF17 TNF receptor superfamily member 17 Blood + 3.80 0.000
29 DTL denticleless E3 ubiquitin protein ligase homolog Blood + 3.80 0.000
30 TOP2A DNA topoisomerase II alpha Blood + 3.80 0.000
31 PI3 peptidase inhibitor 3 Blood - 3.76 0.000
32 GLDC glycine decarboxylase Blood + 3.75 0.000
33 IGLJ3 immunoglobulin lambda joining 3 Blood + 3.75 0.000
34 SESN3 sestrin 3 Blood - 3.75 0.000
35 KIF2C kinesin family member 2C Blood + 3.74 0.000
36 CDT1 chromatin licensing and DNA replication factor 1 Blood + 3.72 0.000
37 CDKN3 cyclin dependent kinase inhibitor 3 Blood + 3.71 0.000
38 PCLAF PCNA clamp associated factor Blood + 3.71 0.000
39 EIF1AY eukaryotic translation initiation factor 1A Y-linked Blood + 3.71 0.034
40 CNTNAP3 contactin associated protein family member 3 Blood - 3.70 0.000
41 CENPA centromere protein A Blood + 3.69 0.000
42 TTK TTK protein kinase Blood + 3.67 0.000
43 ASPM assembly factor for spindle microtubules Blood + 3.66 0.000
44 KIF11 kinesin family member 11 Blood + 3.64 0.000
45 IGL immunoglobulin lambda locus Blood + 3.64 0.000
46 CCNB2 cyclin B2 Blood + 3.61 0.000
47 BUB1B BUB1 mitotic checkpoint serine/threonine kinase B Blood + 3.60 0.000
48 CDC6 cell division cycle 6 Blood + 3.60 0.000
49 SLC2A5 solute carrier family 2 member 5 Blood + 3.60 0.000
50 DUSP5 dual specificity phosphatase 5 Blood + 3.60 0.000
Search GEO for disease gene expression data for Dengue Hemorrhagic Fever.

Pathways for Dengue Hemorrhagic Fever

Pathways related to Dengue Hemorrhagic Fever according to GeneCards Suite gene sharing:

(show top 50) (show all 84)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.11 TNF TLR7 TLR3 STAT2 STAT1 IL6
2
Show member pathways
13.93 TNF TLR7 TLR3 STAT2 STAT1 IL6
3
Show member pathways
13.77 TNF IL6 IL4 IL10 IFNG IFNB1
4
Show member pathways
13.66 TNF STAT2 STAT1 IL6 IL4 IL10
5
Show member pathways
13.52 TNF TLR7 TLR3 STAT2 STAT1 IL6
6
Show member pathways
13.47 TNF STAT2 STAT1 IL6 IL4 IL10
7
Show member pathways
13.29 TNF TLR7 TLR3 STAT2 STAT1 IL4
8
Show member pathways
13.28 TNF TLR7 TLR3 STAT2 STAT1 IL6
9
Show member pathways
13.13 TNF TLR3 STAT2 STAT1 IL6 IL4
10
Show member pathways
13.07 TNF TLR3 STAT2 STAT1 IL6 IFNB1
11 12.99 STAT2 STAT1 IL6 IL4 IFNG IFNAR1
12
Show member pathways
12.99 TNF STAT1 IL6 IL4 IL10 IFNG
13 12.92 TNF TLR3 STAT2 STAT1 IL6 IFNG
14
Show member pathways
12.86 TNF TLR7 TLR3 STAT1 IL6 IFNB1
15
Show member pathways
12.81 TNF IL6 FCGR2A F2 CXCL8
16
Show member pathways
12.73 TNF STAT1 IL6 IL4 IL10 IFNG
17
Show member pathways
12.72 TNF STAT1 IL6 IL4 IL10 IFNG
18
Show member pathways
12.72 TNF STAT1 IL6 IL10 IFNG F2
19
Show member pathways
12.71 TNF IL4 IL10 IFNG IFNAR1
20 12.7 TNF TLR7 TLR3 STAT2 STAT1 IL4
21
Show member pathways
12.69 STAT2 STAT1 IFNG IFNB1 IFNAR1 IFNA1
22
Show member pathways
12.67 TNF IL4 IFNG IFNB1 IFNAR1 IFNA1
23
Show member pathways
12.64 TNF IFNG IFNB1 IFNA1 CXCL8
24
Show member pathways
12.49 TNF IL6 IL4 IFNG F2 ALB
25
Show member pathways
12.47 TNF TLR3 STAT1 IL6 IFNG CXCL8
26
Show member pathways
12.46 TNF IL6 IL4 IFNG CXCL8
27
Show member pathways
12.43 TNF TLR7 TLR3 IL6 IFNB1 CXCL8
28
Show member pathways
12.43 TNF STAT1 IL4 IL10 IFNG FCGR2A
29
Show member pathways
12.42 STAT2 STAT1 IL6 IL4 IL10 IFNG
30
Show member pathways
12.4 TNF IL6 IL10 CXCL8
31
Show member pathways
12.38 TNF STAT2 STAT1 IL6 IL10 CD209
32 12.36 TNF TLR7 TLR3 STAT1 IL6 IFNG
33 12.35 TNF STAT2 STAT1 IL6 IFNB1 IFNAR1
34
Show member pathways
12.29 TNF TLR3 STAT2 STAT1 IFNG IFNB1
35 12.26 TNF IL6 IL10 CXCL8
36 12.26 TNF IL6 IL10 IFNB1 FCGR2A CXCL8
37
Show member pathways
12.25 TNF TLR7 STAT1 IL6 IL4 IFNG
38 12.21 TNF STAT2 STAT1 IFNG IFNB1 IFNAR1
39 12.18 TNF IL6 IL4 IFNG FCGR2A CXCL8
40 12.17 TNF STAT1 IL6 IL10 IFNG IFNB1
41 12.16 TNF STAT2 STAT1 IL6
42 12.16 TNF STAT1 IL6 IL4 IL10 CXCL8
43 12.16 TNF IL6 IL4 IL10 IFNG FCGR2A
44
Show member pathways
12.15 TNF TLR7 TLR3 STAT2 STAT1 IL6
45 12.1 TNF IL6 IL10 IFNG CXCL8
46
Show member pathways
12.09 STAT1 IL4 IFNG HLA-A
47 12.09 TNF STAT1 IL6 F3 CXCL8
48 12.06 IL6 IFNG IFNB1 CXCL8
49
Show member pathways
12.04 TLR7 TLR3 STAT1 IL6 IL4 IFNG
50 11.99 TNF IL6 IFNG CXCL8

GO Terms for Dengue Hemorrhagic Fever

Cellular components related to Dengue Hemorrhagic Fever according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.73 TNF IL6 IL4 IL10 IFNG IFNB1
2 extracellular space GO:0005615 9.44 TNF TLR3 IL6 IL4 IL10 IFNG

Biological processes related to Dengue Hemorrhagic Fever according to GeneCards Suite gene sharing:

(show top 50) (show all 54)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.32 TLR7 TLR3 STAT2 STAT1 IL6 IL4
2 positive regulation of transcription by RNA polymerase II GO:0045944 10.23 TNF TLR3 STAT1 IL6 IL4 IL10
3 adaptive immune response GO:0002250 10.11 IFNG IFNB1 IFNA1 HLA-A CD209
4 inflammatory response GO:0006954 10.08 TNF TLR7 TLR3 IL6 CXCL8
5 positive regulation of gene expression GO:0010628 10.08 TNF TLR3 IL6 IL4 IFNG F3
6 immune response GO:0006955 10.02 TNF TLR7 TLR3 IL6 IL4 IL10
7 blood coagulation GO:0007596 9.99 IFNB1 IFNA1 F3 F2
8 cellular response to lipopolysaccharide GO:0071222 9.96 TNF IL6 IL10 CXCL8
9 response to virus GO:0009615 9.92 TNF TLR3 IFNG IFNB1 IFNAR1
10 positive regulation of inflammatory response GO:0050729 9.91 TNF TLR7 TLR3 IFNG
11 regulation of insulin secretion GO:0050796 9.89 TNF IL6 IFNG
12 interferon-gamma-mediated signaling pathway GO:0060333 9.89 STAT1 IFNG HLA-A
13 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.88 TNF TLR7 TLR3
14 response to glucocorticoid GO:0051384 9.88 TNF IL6 IL10
15 B cell differentiation GO:0030183 9.88 IL4 IL10 IFNB1 IFNA1
16 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.88 TNF IL6 IL4 IFNG
17 positive regulation of interleukin-6 production GO:0032755 9.88 TNF TLR7 TLR3 IL6 IFNG
18 I-kappaB kinase/NF-kappaB signaling GO:0007249 9.87 TNF TLR7 TLR3
19 regulation of protein phosphorylation GO:0001932 9.87 TNF TLR7 STAT2
20 positive regulation of T cell proliferation GO:0042102 9.87 IL6 IL4 CD209
21 positive regulation of interferon-gamma production GO:0032729 9.87 TNF TLR7 TLR3 HLA-A
22 positive regulation of smooth muscle cell proliferation GO:0048661 9.86 TNF STAT1 IL6
23 positive regulation of cytokine production GO:0001819 9.86 TNF TLR3 IL10 IFNG
24 positive regulation of interleukin-1 beta production GO:0032731 9.85 TNF IL6 IFNG
25 positive regulation of interleukin-8 production GO:0032757 9.85 TNF TLR7 TLR3 IL6 F3
26 humoral immune response GO:0006959 9.83 TNF IL6 IFNG IFNB1 IFNA1
27 extrinsic apoptotic signaling pathway GO:0097191 9.82 TNF TLR3 IFNG
28 response to exogenous dsRNA GO:0043330 9.82 TLR3 IFNB1 IFNA1
29 B cell proliferation GO:0042100 9.81 IL10 IFNB1 IFNA1
30 positive regulation of JAK-STAT cascade GO:0046427 9.81 TNF IL6 IL10 F2
31 JAK-STAT cascade GO:0007259 9.8 STAT2 STAT1 IFNG IFNAR1
32 positive regulation of chemokine production GO:0032722 9.8 TNF TLR7 TLR3 IL6 IFNG
33 defense response GO:0006952 9.8 TNF TLR3 STAT2 STAT1 IFNB1 IFNA1
34 positive regulation of interferon-alpha production GO:0032727 9.79 TLR7 TLR3 STAT1
35 cellular response to interferon-beta GO:0035458 9.77 TLR3 STAT1 IFNB1
36 positive regulation of peptidyl-serine phosphorylation of STAT protein GO:0033141 9.77 IFNG IFNB1 IFNA1
37 positive regulation of MHC class II biosynthetic process GO:0045348 9.72 IL4 IL10 IFNG
38 microglial cell activation GO:0001774 9.72 TNF TLR7 TLR3 IL4 IFNG
39 negative regulation of lipid storage GO:0010888 9.71 TNF IL6
40 necroptotic signaling pathway GO:0097527 9.7 TNF TLR3
41 endothelial cell apoptotic process GO:0072577 9.7 TNF IL10
42 vascular endothelial growth factor production GO:0010573 9.68 TNF IL6
43 positive regulation of mononuclear cell migration GO:0071677 9.67 TNF IL4
44 negative regulation of cytokine production involved in immune response GO:0002719 9.67 TNF IL10
45 positive regulation of cellular respiration GO:1901857 9.66 IL4 IFNG
46 neuroinflammatory response GO:0150076 9.65 IL4 IFNG
47 type 2 immune response GO:0042092 9.65 IL4 IL10
48 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.63 TNF IFNG
49 regulation of isotype switching GO:0045191 9.63 IL4 IL10
50 type I interferon signaling pathway GO:0060337 9.63 STAT2 STAT1 IFNB1 IFNAR1 IFNA1 HLA-A

Molecular functions related to Dengue Hemorrhagic Fever according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 growth factor activity GO:0008083 9.46 IL6 IL4 IL10 F2
2 cytokine activity GO:0005125 9.23 TNF IL6 IL4 IL10 IFNG IFNB1
3 cytokine receptor binding GO:0005126 9.13 IL4 IFNB1 IFNA1

Sources for Dengue Hemorrhagic Fever

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....